Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Risk Assessment in Myeloproliferative Neoplasms.

Mayo Clinic proceedings - 1 Aug 2017

Tefferi Ayalew, Vannucchi Alessandro Maria

Abstract excerpt

The World Health Organization classification system recognizes 4 variants of JAK2 mutation-enriched myeloproliferative neoplasms (for expansion of gene symbols, use search tool at www.genenames.org): essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), and prefibrotic PMF. All 4 disorders are characterized by stem cell-derived clonal myeloproliferation with mutually exclusive...

Topics

Join the communities discussing this publication.

Janus Kinase 2
Mutation
Myeloproliferative Disorders
Phenotype
Polycythemia Vera
Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Risk Assessment

Thrombocythemia, Essential

Source

Identifiers

PMID: 28778261
DOI: 10.1016/j.mayocp.2017.06.002

Genes

JAK2
MPL
CALR
ASXL1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Risk Assessment in Myeloproliferative Neoplasms.PMID 28778261Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Genetics of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.Semantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.